Published in AIDS Weekly, April 3rd, 2000
This agreement adds PhenoSense HIV to LabCorp's existing phenotyping and genotyping test menu, further expanding LabCorp's extensive HIV testing services and offering increased physician choice.
The U.S. Food and Drug Administration's (FDA) Antiretroviral Advisory Committee recently concluded that resistance tests should be used to help develop new drugs to combat HIV. In addition, a panel...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.